Roche’s Itovebi™ (inavolisib) significantly improved overall survival in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer patients, according to final Phase III INAVO120 trial results.
Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
Johnson & Johnson MedTech’s MONARCHâ„¢ Platform demonstrated 98.7% navigation success and 83.2% diagnostic yield in the TARGET study, confirming its safety and efficacy for robotically assisted bronchoscopy.
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.
XTANDI® (enzalutamide), co-developed by Astellas and Pfizer, has shown a significant 30% reduction in risk of death over five years in metastatic hormone-sensitive prostate cancer (mHSPC) patients, marking it as the first androgen receptor inhibitor to demonstrate this long-term survival benefit.
The stepwise vaccination approach successfully activated and matured B cells toward producing broadly neutralizing antibodies, marking a major milestone in the pursuit of an effective HIV vaccine.
In addition, the research showed an 80% reduction in the hospitalization risk of cardiovascular disease in individuals with Type 1 diabetes who did not have a previous history of such illnesses.
The VENTANA MET (SP44) RxDx Assay detects the MET, or c-Met, protein, which is overexpressed in about 25% of advanced NSQ-NSCLC patients with EGFR wild-type.
The APHINITY study’s ten-year follow-up results showed that adjuvant Perjeta® (pertuzumab) added to chemotherapy and Herceptin® (trastuzumab) resulted in a clinically significant survival benefit.
